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Abstract
Purpose: To determine the risk factors of severe radiation pneumonitis (RP) after stereotactic body radiation therapy 
(SBRT) for primary or secondary lung tumors.
Materials and methods: From January 2003 to March 2009, SBRT was performed on 117 patients (32 patients before 
2005 and 85 patients after 2006) with lung tumors (primary = 74 patients and metastatic/recurrent = 43 patients) in our 
institution. In the current study, the results on cases with severe RP (grades 4-5) were evaluated. Serum Krebs von den 
Lungen-6 (KL-6) and serum Surfactant protein-D (SP-D) were used to predict the incidence of RP. A shadow of 
interstitial pneumonitis (IP) on the CT image before performing SBRT was also used as an indicator for RP. Since 2006, 
patients have been prescreened for biological markers (KL-6 & SP-D) as well as checking for an IP-shadow in CT.
Results: Grades 4-5 RP was observed in nine patients (7.7%) after SBRT and seven of these cases (6.0%) were grade 5 in 
our institution. A correlation was found between the incidence of RP and higher serum KL-6 & SP-D levels. IP-shadow in 
patient's CT was also found to correlate well with the severe RP. Severe RP was reduced from 18.8% before 2005 to 3.5% 
after 2006 (p = 0.042). There was no correlation between the dose volume histogram parameters and these severe RP 
patients.
Conclusion: Patients presenting with an IP shadow in the CT and a high value of the serum KL-6 & SP-D before SBRT 
treatment developed severe radiation pneumonitis at a high rate. The reduction of RP incidence in patients treated 
after 2006 may have been attributed to prescreening of the patients. Therefore, pre-screening before SBRT for an IP 
shadow in CT and serum KL-6 & SP-D is recommended in the management and treatment of patients with primary or 
secondary lung tumors.
Introduction
Stereotactic body radiation therapy (SBRT) has been
widely used as a safe and effective treatment method for
primary or metastatic lung tumors [1]. According to the
protocol of Japan Clinical Oncology Group (JCOG) 0403
study [2,3], the absolute contraindication to SBRT was
pregnancy. Relative contraindications consisted of (a) a
history of irradiation to the concerned site, (b) severe
interstitial pneumonitis or pulmonary fibrosis, (c) severe
diabetes or connective tissue disease, and (d) common
use of steroids. However, these complications preclude
other treatment methods in some cases and radiation
therapy becomes the only available treatment. Favorable
initial clinical results, and local control rates around 90%
have been reported [4-10].
Although the mechanisms are not completely under-
stood, it is critical to review the biologic factors involved
in radiation lung damage. Current evidence suggests that
many factors and various lung parenchymal cells contrib-
ute to the pathogenesis of radiation lung damage [11].
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Page 2 of 9The progression of radiation-induced damage is the
result of an early activation of an inflammatory reaction
leading to the expression and maintenance of an elevated
cytokine cascade [12]. Kong et al. [13] concluded that
blood biomarkers such as transforming growth factor
(TGF)-beta1, interleukin (IL)-6, krebs von den Lungen-6
(KL-6), surfactant proteins (SP), and IL-1ra could accu-
rately predict radiation-induced lung damage. Serum KL-
6 and SP-D were also evaluated as predictive biomarlers
for radiation pneumonitis (RP) in this study.
For normal tissues, the use of a single dose rather than a
conventional fractionated dose can increase the risk of
complications. However, few cases with severe toxicity
have been reported [14-16]. In the current study, cases of
severe RP (grades 4-5) that received SBRT for lung
tumors in our institution were evaluated. In our previous
report [17], the overall incidence rate of grades 2-5 RP
was 29% (7/25 cases) and three patients (12%) died from
RP from May 2004 to April 2006 at the median follow-up
time of 18 months after completing SBRT. A significant
decrease of the incidence rate of severe RP was observed
for the period entering into 2006. The purpose of this
study was to determine the risk factors of severe RP after
SBRT for primary or secondary lung tumors.
Methods and materials
Subjects
From January 2003 to March 2009, SBRT was performed
on 117 patients with lung tumors in our institution. SBRT
was performed for primary lung cancers in 74 cases (63%)
and for metastatic or recurrent lung tumors in 43 cases
(37%) (Table 1). These consecutive 117 patients were
evaluated retrospectively. There were 98 males and 19
females, and the median age was 72 years (range; 28-84
years). Thirteen patients (11%) had a shadow of intersti-
tial pneumonitis (IP) in the CT before SBRT, 23 patients
(20%) had high serum KL-6 value, and 19 patients (16%)
had high SP-D value. The upper limit of serum KL-6 and
SP-D was defined as 500.0 U/mL and 110.0 ng/mL,
respectively.
All patients enrolled in this study satisfied the following
eligibility criteria: a) solitary or double lung tumors; b)
tumor diameter < 40 mm; c) no evidence of regional
lymph node metastasis; d) Karnofsky performance status
scale > or = 80%; and e) tumor not located adjacent to
major bronchus, esophagus, spinal cord, or great vessels.
Patients with an active malignant lesion other than lung
were excluded. Therefore, no chemotherapy was com-
bined with SBRT. There were 32 patients (27%) who were
treated before 2005. After 2006, patients with a high risk
for RP who had an obvious IP shadow on CT with a 3-
mm slice before SBRT together with a high value of
serum KL-6 & SP-D were excluded from receiving SBRT.
In the high resolution chest CT, IP shadow was defined
as a mandatory observation beneath the pleura and a
honeycomb lung. IP shadows were graded by their radio-
graphically estimated total lung volume as follows: slight,
less than 10%; moderate, 10-50%; and severe, >50%.
Planning procedure and treatment
The treatment methods which included the definition of
the internal target volume (ITV) were performed accord-
ing to JCOG 0403 phase II protocol [2,3]. The following
gives a brief description of the treatment methods, which
were described in detail in our previous report [17]. SBRT
was performed daily with a central dose of 48 Gy in four
fractions over 4-8 days. Each CT slice was scanned with
an acquisition time of four seconds to include the whole
phase of one respiratory cycle. The axial CT images were
transferred to a 3-dimension RT treatment-planning
machine (Pinnacle3, New Version 7.4i, Philips). Spicula
formation and pleural indentation were included within
the ITV. The mediastinal lymph nodes were not included
from the irradiation field. The setup margin (SM)
between ITV and the planning target volume (PTV) was
5 mm in all directions. There was an additional 5 mm leaf
margin to PTV, according to JCOG0403 protocol, in
order to make the dose distribution within the PTV more
homogeneous. No pairs of parallel opposing fields were
used. The target reference point dose was defined at the
isocenter of the beam. The iso-dose distribution of an
SBRT treatment was shown in Figures 123.
The dose limitation for pulmonary parenchyma was
mean lung dose (MLD) < 18.0 Gy, percentage of total lung
volume receiving greater than or equal to 20 Gy (V20) <
20%, and V15 < 25% according to JCOG0403 protocol.
Radiation method
SBRT was given in at least 8 ports by linear accelerator
(Elekta Synergy System, Elekta Ltd, Crawley, UK) after
the Synergy system was available in our institution from
February 2007. At least eight beams (I-rotation angle was
0 degree only in two beams) were used. CT verification of
Table 1: Characteristics of the tumor
Subject N (%)
Biopsy proved primary lung cancer 60 51
cT1N0M0 39 33
cT2N0M0 19 16
the others 2 2
Unconfirmed histology (suspected of 
primary lung cancer)
14 12
Metastatic or recurrent lung cancer 43 37
Total 117 100
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Figure 1 An example of dose distribution of SBRT (Pt. No. 5).
Figure 2 An example of dose distribution of SBRT (Pt. No. 7).
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session using a kilovoltage-based cone-beam CT (CBCT)
unit in the same room and in a treatment position. The
Linac machine was Elekta Synergy with the cone-beam
CT. The details of the radiation method before 2007 were
described in our previous report [17]. The collapsed cone
(CC) convolution method in Pinnacle3 was used as the
heterogeneous correction method for lung. The breath-
ing suppression was done with a body frame and an
abdominal pressure board (Figure 4).
Definition of RP grading
The toxicity data were collected retrospectively from the
patient files. Basically, the RP grading system used fol-
lowed the Common Terminology Criteria for Adverse
Events (CTCAE) v3.0, and the grades were as follows:
Grade 1, asymptomatic (radiographic findings only);
Grade 2, radiographic findings plus symptomatic and not
interfering with activities of daily living (ADL); Grade 3,
radiographic findings plus symptomatic and interfering
with ADL or O2 indicated; Grade 4, radiographic findings
plus life-threatening (ventilatory support indicated), and
Grade 5, radiographic findings plus death. Patients with
mild pulmonary CT changes after SBRT were categorized
as Grade 1. The radiographic findings common to the 5
grades were (a) shadow distribution just beneath pleura,
(b) honeycomb lung, (c) traction bronchitis/dilation of
small bronchus, (d) ground-glass opacity (GGO), or (e)
infiltrative shadow (consolidation), which was not recog-
nized in the CT before SBRT.
Follow-up
CT exams with 3-mm slices were performed at 2, 4, 6, 9,
12, 15, 18, and 24 months after SBRT for asymptomatic
Figure 4 Body frame and abdominal pressure board.
Figure 3 An example of dose distribution of SBRT (Pt. No. 8).
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6, SP-D, white blood cell (WBC), lactate dehydrogenase
(LDH), C-reactive protein (CRP), and tumor markers
were measured in the blood plus an oxygen saturation
was measured from a fingertip.
Statistical Analysis
The relationship between G4-5 RP and pre-SBRT factors
was compared with the X2 test. The cumulative probabil-
ity of RP was calculated and drawn applying the Kaplan-
Meier algorithms with day of treatment as the starting
point. Subgroups were compared using log-rank statis-
tics. Values of p < 0.05 were considered statistically signif-
icant. Statistical calculations were conducted using
version 5.0 StatView software (SAS Institute, Cary, NC).
Results
The median follow up time for all 117 patients was 14.7
months (range; 0.3-76.2 months). The control rate within
the radiation field was 86.3% (101/117 cases).
RP of grade 4 or higher was observed in nine patients
(7.7%) and the median time of showing symptoms was 4.0
months (range; 0.4-6.0 months) (Table 2). All of these
nine RPs were due to acute exacerbation of IP (Figures
5678910) and steroid pulse therapy combined with an
oral anti-pneumocystis carinii drug was administered to
these patients. Grade 4 RP with intubation was seen in
two cases and the other seven cases were grade 5. Grade 3
RP was seen in two patients during this time period.
Grade 4 or higher RP was noted in six out of 32 patients
(18.8%) before 2005 and in only three out of 85 patients
(3.5%) after 2006 (Figure 11). This difference had a statis-
tical significance (log-rank p = 0.042 and X2 p = 0.018).
Serum KL-6 was determined in 8 of the 9 patients with
grades 4-5 RP and in 95 of the 108 patients with grades 0-
3 RP. Of the 8 patients with grades 4-5 RP, serum KL-6
(U/mL) was elevated in 6 patients (75%) (Table 2). Serum
SP-D was determined in 7 patients with grades 4-5 RP
and in 93 patients with grades 0-3 RP. Of the 7 patients
with grades 4-5 RP, serum SP-D (ng/mL) was evaluated in
5 patients (71%) (Table 2). Additionally, the IP shadow
was seen in seven cases (78%) in the CT before SBRT
within or outside of radiation field. The radiation dose
prescribed was within the protocol in all 117 patients.
The appearance of grades 4-5 RP and serum KL-6 value
(1-year cumulative incidence; 32% vs. 3% and log-rank p
< 0.0001 & X2 p = 0.0002), SP-D value (1-year; 29% vs. 3%
and log-rank p = 0.0001 & X2 p = 0.0002), or IP shadow in
CT before SBRT (1-year; 57% vs. 2% and log-rank p <
Figure 5 CT images before SBRT (Pt. No. 5).
Table 2: Characteristics of nine patients with G4-5 of RP
Case 
No.















1 950? 286? moderate 5 3.0 Mo Postop
erative
6.7 2.7 938 IV 26.4 46.29 Lt hilum
2 582? 95 slight 5 2.0 Mo Fresh 7.6 1.9 568 IA 47.5 45.57 Lt hilum
3 852? 136? severe 5 6.0 Mo Postop
erative
11.2 4.6 791 IV 120.9 45.00 Rt S6
4 1590? NA slight 5 6.0 Mo Fresh 5.6 1.9 426 IA 29.4 44.05 Rt S10
5 NA NA (-) 4 0.4 Mo Fresh 5.0 1.5 291 IA 42.5 47.80 Lt S8
6 289 101 slight 5 5.9 Mo Fresh 7.0 2.0 440 IA 56.5 48.90 Rt S10
7 497 321? (-) 4 4.0 Mo Postop
erative
2.6 0.9 269 IV 7.7 45.48 Lt S10
8 833? 135? slight 5 2.1 Mo Fresh 6.3 2.3 492 IA 20.9 47.62 Rt S5
9 883? 235? slight 5 1.0 Mo Fresh 3.7 0.7 288 IB 23.9 44.80 Rt S2
(0-500) (0-110)
Abbreviation ; NA = not available
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(Table 3).
The risk factors of RP other than serum KL-6, SP-D,
and IP shadow in CT are shown in Table 4. The mean
PTV for nine patients with severe RP was 29.4 cc (range:
7.7-120.9 cc) and was 42.5 cc (range: 7.5-239.4 cc) of for
the other low-grade RP patients. None of these risk fac-
tors were different for those patients with and without
grades 4-5 RP.
Discussion
This was a retrospective study to evaluate the incidence
rate and risk factors of severe RP after SBRT for primary
(74 patients), metastatic and recurrent (43 patients) lung
tumors. Grades 4-5 RP were noted in 9 patients (7.7%); IP
shadow in the CT, and high serum KL-6 & SP-D values
before SBRT showed positive correlations with grades 4-5
RP. Seven of the 117cases (6.0%) were of grade 5 in our
institution. After 2006, severe grades 4-5 RP were signifi-
cantly reduced.
According to Borst et al. [15], the crude incidence rate
of grade 2 RP was 10.9% for the SBRT on 128 patients
with malignant pulmonary lesions who were treated with
6-12 Gy per fraction with a median MLD of 6.4 Gy
(range: 1.5-26.5 Gy). According to Rusthoven et al. [16],
grades 2-3 RP was rare, occurring in only one out of 38
patients (2.6%) with one to three lung metastases after
SBRT of 48-60 Gy in 3 fractions. They used the dose con-
Figure 6 CT images of radiation pneumonitis after SBRT (Pt. No. 
5). The finding was acute exacerbation of IP.
Figure 8 CT images of radiation pneumonitis (acute exacerbation 
of IP) after SBRT (Pt. No. 7).
Figure 7 CT images before SBRT (Pt. No. 7). Figure 9 CT images before SBRT (Pt. No. 8).
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Page 7 of 9straint of V15 < 35%. According to Nagata et al. [1], no
severe symptomatic pulmonary complications (NCICTC
Grade 3 or larger) were encountered. Timmerman et al.
[14] reported in 2006 that a SBRT treatment dose of 60-
66 Gy total in three fractions was administered during 1
to 2 weeks for 70 patients with clinically staged T1-
2N0M0 (tumor size < or = 7 cm) biopsy-confirmed non-
small cell lung cancer (NSCLC). This resulted in toxicity
of grades 3 to 5 in a total of 14 patients (20%) and grade 5
was seen in four patients (5.7%). Le QT et al. [18]
reported in 2006 that after single-fraction SBRT (15-30
Gy) was performed for 32 patients (21 NSCLC and 11
metastatic tumors), two patients (6%) suffered from RP of
grade 5.
Moreover, according to Rusthoven et al. [16], patients
were required to have adequate lung function, which was
defined as stable arterial hemoglobin saturation above
90% with minimal exertion, forced expiratory volume
(FEV) of 1.0% higher than the predicted value of 40% or
more than 1 L and carbon monoxide diffusing capacity
(DLCO) higher than the predicted 40% value. In our insti-
tution, the exclusion criteria of SBRT consisted of an FEV
of 1.0% at less than 750 mL, and an obvious IP shadow on
the roentgen examination according to JCOG 0403 pro-
tocol.
RP of grades 4-5 occurred in six out of 32 patients
(18.8%) before 2005 and in only three out of 85 patients
(3.5%) after 2006 (Figure 11). The significant reduction of
severe grades 4-5 RP after 2006 in our institution is
believed to be due to the selection of appropriate
patients. After 2006, patients were excluded from SBRT if
they had an obvious IP shadow on the CT-scan (slice
thickness 3.0 mm), and if serum KL-6 and SP-D levels
were high. All of the severe RP cases in our institution
consisted of acute exacerbation of IP outspreading over
the radiation field. Admittedly, these nine patients with
severe RP represent a small sample. Whether our results
are a coincidence that biomarkers and CT shadows are
indeed significantly different in patients with grades 4-5
toxicity compared to patients without RP awaits confir-
mation in further studies.
KL-6 is the indicator that specificity is high for IP and is
clinically evaluated for the purpose of diagnosing IP. In
addition, KL-6 is important as an index of the activity of
IP because it becomes significantly high for IP with activ-
Figure 10 CT images of radiation pneumonitis (acute exacerba-
tion of IP) after SBRT (Pt. No. 8).
Table 3: Relationship between G4-5 RP and pre-SBRT factors
Pre-SBRT 
factors






high value 6 17 23 p = 0.0002 32% p < 0.0001
within normal 
level
2 78 80 3%
not available 1 13 14
Serum SP-D
high value 5 14 19 p = 0.0002 29% p = 0.0001
within normal 
level
2 79 81 3%
not available 2 15 17
IP shadow in 
CT
(+) 7 6 13 p < 0.0001 57% p < 0.0001
(-) 2 102 104 2%
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alveolus epithelial cell. However, KL-6 develops in a type
II alveolus epithelial cell, in a bronchial epithelial cell, and
in a bronchus gland cell. The expression of KL-6
increases in the hyperplasia of the type II of alveolus epi-
thelial cell in IP. A small quantity of KL-6 is present in the
liquid coating the alveolus in normal lungs, and its den-
sity increases during hyperplasia of the type II alveolus
epithelial cell for IP. In addition, because inflammation
occurs, blood vessel permeability rises, and KL-6 in the
Table 4: Risk factors of severe RP
Patients with G4-5 RP Patients without G4-5 RP p value




mean +/- SD 3.27 +/- 0.65 2.75 +/- 0.85 N.S.
range 2.76-4.01 1.54-4.07
FEV 1.0 (L)
mean +/- SD 2.11 +/- 0.68 1.87 +/- 0.82 N.S.
range 1.59-3.24 0.59-3.24
K-PS (%)
90 5 (56%) 52 (48%) N.S.
80 4 (44%) 56 (52%)
Age (y)
mean +/- SD 73.3 +/- 6.8 70.1 +/- 14.1 N.S.
range 68-80 24-93
COPD
With 2 (22%) 22 (20%) N.S.
Without 8 (78%) 86 (80%)
Treatment specific factors
Size of the PTV (cc)
mean +/- SD 29.4 +/- 33.2 42.5 +/- 13.7 N.S.
range 7.7-120.9 7.5-239.4
Mean lung dose (Gy)
mean +/- SD 5.0 +/- 2.3 4.2 +/- 1.4 N.S.
range 2.7-9.4 1.7-7.9
Lung V20 (%)
mean +/- SD 5.9 +/- 2.7 5.8 +/- 2.6 N.S.
range 2.6-11.2 1.0-11.0
Target location
Central 2 (22%) 17 (16%) N.S.
Peripheral 7 (78%) 91 (84%)
Abbreviation:
COPD = chronic obstructive pulmonary diseases
RP = radiation pneumonitis
G4-5 = grades 4-5
PTV = planning target vlume
FEV = Forced expiratory volume
K-PS = Karnofsky Performance status
N.S. = not significant
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result, KL-6 in the blood rises in the IP. When an injury to
the lung stroma is evaluated, KL-6, SP-A, SP-D, and
MCP-1 are examined. Of these, there is a report that KL-
6 was highest in both sensitivity (93.9%) and specificity
(96.3%) [19]. Furthermore, SP-D levels at 50 to 60 Gy
(midway during radiation therapy) showed greater sensi-
tivity and positive predictive values for RP detection (74%
and 68%, respectively) than SP-A (26% and 21%, respec-
tively) [20].
Conclusion
The frequency of severe RP in our institution has recently
shown a decrease, by prescreening patients for serum
KL-6 and SP-D as biomarkers of severe RP. When SBRT
was performed on patients presenting with an IP shadow
in CT and a high value of serum KL-6 before treatment,
severe radiation pneumonitis occurred at a high rate.
Therefore, pre-screening of patients before SBRT appears
to be a useful strategy in treating lung tumors.
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Figure 11 Cumulative probability curves of severe radiation 
pneumonitis of grades 4-5 divided by pre-2005 (old group) and 
post-2006 (new group).
Old (N=32) 1y: 19.17.0%
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